Erscheint 6 Ausgaben pro Jahr
ISSN Druckformat: 1040-8401
ISSN Online: 2162-6472
Indexed in
Overexpressed Cell Surface Interleukin-4 Receptor Molecules Can Be Successfully Targeted for Antitumor Cytotoxin Therapy
ABSTRAKT
A variety of human solid cancer cell lines and primary cell cultures has been reported to overexpress high-affinity receptors (R) for interleukin-4 (IL-4), a pleiotropic immunoregulatory cytokine. The significance of IL-4R expression is not known; however, IL-4 is able to upregulate adhesion molecules, inhibit cell proliferation, and mediate signal transduction in tumor cell lines. To target IL-4R, we produced a chimeric protein composed of a circular permuted IL-4 and a mutated form of Pseudomonas exotoxin [termed IL4(38-37)-PE38KDEL or cpIL4-PE]. The recombinant cpIL4-PE was highly cytotoxic to cancer cells, but not toxic to normal B cells, T cells, monocytes, and CD34+, even though these cells express detectable numbers of IL-4R. The cytotoxicity was specific because excess of recombinant IL-4 neutralized the cpIL4-PE effect. To further develop this molecule, in vivo antitumor activity was tested in animal models of human cancer. This agent showed remarkable antitumor activity in AIDS-Kaposis sarcoma, glioblastoma multiforme, and breast cancer models in immunodeficient animals. cpIL4-PE caused partial or complete regression of established human tumors. Preclinical efficacy and toxicity studies provided a therapeutic window in which this cancer-targeted agent could be used. On the basis of these studies, we initiated a Phase I clinical trial for the treatment of recurrent glioblastoma multiforme. Our preliminary clinical results suggest that cpIL4-PE has antitumor activity against the deadliest form of brain tumors, without detectable toxicity to normal brain tissues. Thus, IL-4 receptors represent novel targets for cancer cytotoxin therapy.
-
Lima Flavia R.S., Kahn Suzana Assad, Soletti Rossana C., Biasoli Deborah, Alves Tercia, da Fonseca Anna Carolina C., Garcia Celina, Romão Luciana, Brito José, Holanda-Afonso Rosenilde, Faria Jane, Borges Helena, Moura-Neto Vivaldo, Glioblastoma: Therapeutic challenges, what lies ahead, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1826, 2, 2012. Crossref
-
Garland Linda, Gitlitz Barbara, Ebbinghaus Scot, Pan Henry, de Haan Hans, Puri Raj K, Von Hoff Daniel, Figlin Robert, Phase I Trial of Intravenous IL-4 Pseudomonas Exotoxin Protein (NBI-3001) in Patients with Advanced Solid Tumors That Express the IL-4 Receptor, Journal of Immunotherapy, 28, 4, 2005. Crossref
-
Long Ton That Ai, Kalantarov Gavreel, Chudner Alexandra, Trakht Ilya, A Dual-Chamber System for Screening Cytotoxic Effects of Hybridoma-Produced Antibodies, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 32, 4, 2013. Crossref
-
Zhu Xiaoying, Tao Kun, Li Yajuan, Li Shenfeng, Zhang Lijun, Wang Dong, Zhong Liang, Feng Wenli, A new recombinant immunotoxin hscFv-ETA’ demonstrates specific cytotoxicity against chronic myeloid leukemia cells in vitro, Immunology Letters, 154, 1-2, 2013. Crossref
-
Klementiev Boris, Enevoldsen Maj N., Li Shizhong, Carlsson Robert, Liu Yawei, Issazadeh-Navikas Shohreh, Bock Elisabeth, Berezin Vladimir, Antiinflammatory properties of a peptide derived from interleukin-4, Cytokine, 64, 1, 2013. Crossref
-
Prokopchuk O, Liu Y, Henne-Bruns D, Kornmann M, Interleukin-4 enhances proliferation of human pancreatic cancer cells: evidence for autocrine and paracrine actions, British Journal of Cancer, 92, 5, 2005. Crossref
-
Newman Gale, Gonzalez-Perez Ruben Rene, Leptin–cytokine crosstalk in breast cancer, Molecular and Cellular Endocrinology, 382, 1, 2014. Crossref
-
Li Yan Michael, Hall Walter A., Targeted Toxins in Brain Tumor Therapy, Toxins, 2, 11, 2010. Crossref
-
Ishige Kazunori, Shoda Junichi, Kawamoto Toru, Matsuda Sachiko, Ueda Tetsuya, Hyodo Ichinosuke, Ohkohchi Nobuhiro, Puri Raj K., Kawakami Koji, Potentin vitroandin vivoantitumor activity of interleukin-4-conjugatedPseudomonasexotoxin against human biliary tract carcinoma, International Journal of Cancer, 123, 12, 2008. Crossref
-
Hansen Morten, Hjortø Gertrud M., Met Özcan, Jakobsen Mogens H., Svane Inge M., Larsen Niels B., Cell culture plastics with immobilized interleukin-4 for monocyte differentiation, Journal of Biomedical Materials Research Part A, 96A, 2, 2011. Crossref
-
Carlson Linda E., Speca Michael, Patel Kamala D., Goodey Eileen, Mindfulness-Based Stress Reduction in Relation to Quality of Life, Mood, Symptoms of Stress, and Immune Parameters in Breast and Prostate Cancer Outpatients, Psychosomatic Medicine, 65, 4, 2003. Crossref
-
Rustamzadeh Edward, Low Walter C., Vallera Daniel A., Hall Walter A., Immunotoxin therapy for CNS tumor, Journal of Neuro-oncology, 64, 1-2, 2003. Crossref
-
Kurtz David M., Tschetter Loren K., Allred Jacob B., Geyer Susan M., Kurtin Paul J., Putnam Wesley D., Rowland Kendrith M., Wiesenfeld Martin, Soori Gamini S., Tenglin Richard C., Bernath Albert M., Witzig Thomas E., Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51, Leukemia & Lymphoma, 48, 7, 2007. Crossref
-
Chi Lianhua, Na Moon-Hee, Jung Hyun-Kyung, Vadevoo Sri Murugan Poongkavithai, Kim Cheong-Wun, Padmanaban Guruprasath, Park Tae-In, Park Jae-Yong, Hwang Ilseon, Park Keon Uk, Liang Frank, Lu Maggie, Park Jiho, Kim In-San, Lee Byung-Heon, Enhanced delivery of liposomes to lung tumor through targeting interleukin-4 receptor on both tumor cells and tumor endothelial cells, Journal of Controlled Release, 209, 2015. Crossref
-
Landi Stefano, Bottari Fabio, Gemignani Federica, Gioia-Patricola Lydie, Guino Elisabeth, Osorio Alfonso, Oca Javier de, Capella Gabriel, Canzian Federico, Moreno Victor, Interleukin-4 and interleukin-4 receptor polymorphisms and colorectal cancer risk, European Journal of Cancer, 43, 4, 2007. Crossref
-
Beseth Bryce D, Cameron Robert B, Leland Pamela, You Liang, Varricchio Frederick, Kreitman Robert J, Maki Richard A, Jablons David M, Husain Syed R, Puri Raj K, Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts, The Annals of Thoracic Surgery, 78, 2, 2004. Crossref
-
Kay Neil E., Pittner Brian T., IL-4 Biology: Impact on Normal and Leukemic CLL B Cells, Leukemia & Lymphoma, 44, 6, 2003. Crossref
-
Yang Chih-Yung, Liu Hong-Wen, Tsai Ya-Ching, Tseng Ju-Yu, Liang Shu-Ching, Chen Chin-Yau, Lian Wei-Nan, Wei Ming-Cheng, Lu Maggie, Lu Ruey-Hwa, Lin Chi-Hung, Jiang Jeng-Kai, Interleukin-4 receptor-targeted liposomal doxorubicin as a model for enhancing cellular uptake and antitumor efficacy in murine colorectal cancer, Cancer Biology & Therapy, 16, 11, 2015. Crossref
-
Frankel Arthur E., Kreitman Robert J., CLL immunotoxins, Leukemia Research, 29, 9, 2005. Crossref
-
Kawakami Koji, Kawakami Mariko, Puri Raj K, Cytokine receptor as a sensitizer for targeted cancer therapy, Anti-Cancer Drugs, 13, 7, 2002. Crossref
-
Kay Neil E., Bone Nancy D., Lee Yean K., Jelinek Diane F., Leland Pamela, Battle Traci E., Frank David A., Puri Raj K., A recombinant IL-4-Pseudomonas exotoxin inhibits protein synthesis and overcomes apoptosis resistance in human CLL B cells, Leukemia Research, 29, 9, 2005. Crossref
-
Yoon Dennis J., Liu Christina T., Quinlan Devin S., Nafisi Parsa M., Kamei Daniel T., Intracellular Trafficking Considerations in the Development of Natural Ligand-Drug Molecular Conjugates for Cancer, Annals of Biomedical Engineering, 39, 4, 2011. Crossref
-
Kawakami Koji, Kawakami Mariko, Kioi Mitomu, Husain Syed R., Puri Raj K., Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model, Journal of Neurosurgery, 101, 6, 2004. Crossref
-
Ul-Haq Zaheer, Naz Sehrish, Mesaik M. Ahmed, Interleukin-4 receptor signaling and its binding mechanism: A therapeutic insight from inhibitors tool box, Cytokine & Growth Factor Reviews, 32, 2016. Crossref
-
Ingram Nicola, Northwood Emma L., Perry Sarah L., Marston Gemma, Snowden Helen, Taylor John C., Scott Nigel, Bishop D. Timothy, Coletta P. Louise, Hull Mark A., Reduced type II interleukin-4 receptor signalling drives initiation, but not progression, of colorectal carcinogenesis: evidence from transgenic mouse models and human case–control epidemiological observations, Carcinogenesis, 34, 10, 2013. Crossref
-
Krajewska Julia B., Bartoszek Adrian, Fichna Jakub, New Trends in Liposome-based Drug Delivery in Colorectal Cancer, Mini-Reviews in Medicinal Chemistry, 19, 1, 2018. Crossref
-
Kay Neil E., Hamblin Terry J., Jelinek Diane F., Dewald Gordon W., Byrd John C., Farag Sherif, Lucas Margaret, Lin Thomas, Chronic Lymphocytic Leukemia, Hematology, 2002, 1, 2002. Crossref
-
Kawakami Koji, Puri Raj K., Interleukin-4/13 and Cancer, in Cytokines in the Genesis and Treatment of Cancer, 2007. Crossref
-
Kawakami Mariko, Kawakami Koji, Kioi Mitomu, Leland Pamela, Puri Raj K., Hodgkin lymphoma therapy with interleukin-4 receptor–directed cytotoxin in an infiltrating animal model, Blood, 105, 9, 2005. Crossref
-
Bai Xue-Di, Cao Xue-Wei, Chen Yi-Hui, Fu Long-Yun, Zhao Jian, Wang Fu-Jun, Constructing a better binding peptide for drug delivery targeting the interleukin-4 receptor, Journal of Drug Targeting, 28, 9, 2020. Crossref
-
Green Daniel S, Husain Syed R, Johnson Chase L, Sato Yuki, Han Jing, Joshi Bharat, Hewitt Stephen M, Puri Raj K, Zoon Kathryn C, Combination immunotherapy with IL-4 Pseudomonas exotoxin and IFN-α and IFN-γ mediate antitumor effects in vitro and in a mouse model of human ovarian cancer, Immunotherapy, 11, 6, 2019. Crossref
-
Shi Jingwei, Song Xujun, Traub Benno, Luxenhofer Michael, Kornmann Marko, Involvement of IL-4, IL-13 and Their Receptors in Pancreatic Cancer, International Journal of Molecular Sciences, 22, 6, 2021. Crossref
-
Eguchi J, Hiroishi K, Ishii S, Baba T, Matsumura T, Hiraide A, Okada H, Imawari M, Interleukin-4 gene transduced tumor cells promote a potent tumor-specific Th1-type response in cooperation with interferon-α transduction, Gene Therapy, 12, 9, 2005. Crossref
-
Burt Bryan M., Bader Andrew, Winter Daniel, Rodig Scott J., Bueno Raphael, Sugarbaker David J., Expression of Interleukin-4 Receptor Alpha in Human Pleural Mesothelioma Is Associated with Poor Survival and Promotion of Tumor Inflammation, Clinical Cancer Research, 18, 6, 2012. Crossref
-
Shimamura Takeshi, Royal Richard E., Kioi Mitomu, Nakajima Atsushi, Husain Syed R., Puri Raj K., Interleukin-4 Cytotoxin Therapy Synergizes with Gemcitabine in a Mouse Model of Pancreatic Ductal Adenocarcinoma, Cancer Research, 67, 20, 2007. Crossref
-
Kim Hag Dong, Yu Su-Jin, Kim Hee Suk, Kim Yong-Jin, Choe Jeong Min, Park Yun Gyu, Kim Joon, Sohn Jeongwon, Interleukin-4 Induces Senescence in Human Renal Carcinoma Cell Lines through STAT6 and p38 MAPK, Journal of Biological Chemistry, 288, 40, 2013. Crossref
-
Li Zhiguang, Jiang Jing, Wang Zibing, Zhang Jinhua, Xiao Mingjie, Wang Chunhui, Lu Yu, Qin Zhihai, Endogenous Interleukin-4 Promotes Tumor Development by Increasing Tumor Cell Resistance to Apoptosis, Cancer Research, 68, 21, 2008. Crossref
-
Li Yan Michael, Hall Walter A, Cell Surface Receptors in Malignant Glioma, Neurosurgery, 69, 4, 2011. Crossref
-
Kioi Mitomu, Takahashi Satoru, Kawakami Mariko, Kawakami Koji, Kreitman Robert J., Puri Raj K., Expression and Targeting of Interleukin-4 Receptor for Primary and Advanced Ovarian Cancer Therapy, Cancer Research, 65, 18, 2005. Crossref
-
Kawakami Koji, Kawakami Mariko, Puri Raj K., IL-13 Receptor-Targeted Cytotoxin Cancer Therapy Leads to Complete Eradication of Tumors with the Aid of Phagocytic Cells in Nude Mice Model of Human Cancer, The Journal of Immunology, 169, 12, 2002. Crossref